Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gritstone Oncology Inc (GRTS)

Gritstone Oncology Inc (GRTS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 422,945
  • Shares Outstanding, K 48,952
  • Annual Sales, $ 4,040 K
  • Annual Income, $ -105,310 K
  • 60-Month Beta 0.18
  • Price/Sales 107.31
  • Price/Cash Flow N/A
  • Price/Book 2.52
Trade GRTS with:

Options Overview

Details
  • Implied Volatility 136.50%
  • Historical Volatility 102.14%
  • IV Percentile 28%
  • IV Rank 11.32%
  • IV High 415.18% on 01/27/21
  • IV Low 100.95% on 03/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 79
  • Volume Avg (30-Day) 143
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 2,920
  • Open Int (30-Day) 1,037

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.46
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -0.53
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +35.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.17 +8.08%
on 04/16/21
13.99 -36.88%
on 03/22/21
-4.79 (-35.17%)
since 03/19/21
3-Month
8.17 +8.08%
on 04/16/21
35.20 -74.91%
on 01/20/21
-13.44 (-60.35%)
since 01/19/21
52-Week
2.54 +248.32%
on 11/05/20
35.20 -74.91%
on 01/20/21
+1.17 (+15.27%)
since 04/17/20

Most Recent Stories

More News
Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC

- Preliminary Data from Phase 1 Study of CORAL Expected Mid-year -

GRTS : 8.81 (+1.97%)
Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 0.00% and 12.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?...

GRTS : 8.81 (+1.97%)
Gritstone Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the fourth...

GRTS : 8.81 (+1.97%)
Gritstone Announces Promotions Within its Leadership Team

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced two promotions within its...

GRTS : 8.81 (+1.97%)
Gritstone Oncology, Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GRTS : 8.81 (+1.97%)
Gritstone to Present at the H.C. Wainwright Global Life Sciences Conference

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D.,...

GRTS : 8.81 (+1.97%)
Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand

Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.

GILD : 65.87 (-1.50%)
GSK : 37.87 (+0.32%)
GLPG : 78.59 (-0.71%)
GRTS : 8.81 (+1.97%)
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure

Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today...

GILD : 65.87 (-1.50%)
GRTS : 8.81 (+1.97%)
Moving Average Crossover Alert: Gritstone Oncology (GRTS)

Gritstone Oncology (GRTS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

GRTS : 8.81 (+1.97%)
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

ALXN : 165.06 (+0.84%)
LXRX : 4.95 (-1.98%)
ACRS : 25.98 (-2.62%)
BHVN : 73.12 (-1.72%)
GRTS : 8.81 (+1.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict...

See More

Key Turning Points

3rd Resistance Point 9.64
2nd Resistance Point 9.25
1st Resistance Point 8.95
Last Price 8.81
1st Support Level 8.25
2nd Support Level 7.86
3rd Support Level 7.56

See More

52-Week High 35.20
Fibonacci 61.8% 22.72
Fibonacci 50% 18.87
Fibonacci 38.2% 15.01
Last Price 8.81
52-Week Low 2.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar